Floriano-Sánchez E, Cárdenas-Rodríguez N, Castro-Marín M, Reyes EJL, Flores-Terrazas JE, Carlos-Vera A, Torres-Salazar JJ

Language: Spanish
References: 13
Page: 159-162
PDF size: 181.01 Kb.

ABSTRACT

Background: Recent reports place prostate cancer as the third most common cause of death from cancer in the worldwide male population. In Mexico it is the principal cause of death from cancer in men and more than 70% of those cases are in advanced stages. Several genetic markers involved in prostate cancer are currently being studied. Manganese superoxide dismutase (Mn-SOD) is associated with cancer, but there are very few studies in the literature analyzing this relation. Therefore, the objective of the present study was to evaluate the existence of alterations in Mn-SOD levels in prostate cancer and benign prostatic hyperplasia.
Materials and methods: Eighty samples, 50% of which corresponded to benign prostatic hyperplasia and 50% to prostate cancer, were obtained. Immunohistochemical diagnostic method was standardized for the detection of Mn-SOD in tissue.
Results: The percentage of Mn-SOD immunoreactive area was 24.83±10.5% in prostate cancer and 14.73±8.7% in benign prostatic hyperplasia.
Conclusions: Mn-SOD expression levels in prostate cancer were significantly higher than those in benign prostatic hyperplasia, suggesting that this gene could be used as a tumor marker in biopsies in patients suspected of presenting with prostate cancer.

REFERENCES

1. Prostate cancer risk management: in association with the NHS Cancer Screening Programs; http://cds.bmjlearning.com/learningcds/index.jsp.

2. Fleshner N, Trachtenberg J. New developments and controversies in androgen derivation therapy for advanced prostatic carcinoma. AUA. Update Series. Lesson;1997.

3. Haas GP, Sakr WA. Epidemiology of prostate cancer. CA Cancer J Clin 1997;47(5):273-87.

4. Barry MJ. Epidemiology and Natural History of benign prostatic hyperplasia. R. Urol Clin North Am. 1990;17(3):495-507.

5. Hall SE, Holman CD, Wisniewski ZS, Semmens J. Prostate cancer: socio-economic, geographical and private-health insurance effects on care and survival. BJU Int. 2005;95(1):51-8.

6. St. Clair D, Wan XS, Kuroda M, Vichitbandha S, Tsuchida E, Urano M. Supresion of Tumor Metastasis by Manganeso Superoxide-Dismutase is associated with reduced tumorigenicity and elevated fibronectin. Oncol Rev. 1997;4:753-757.

7. Mc Cord JM, Fridovich I. An enzyme base theory of obligate anaerobius: the physiological function of superoxide dismutase. Proc Natl Acad Sci. 1974;41:35-95.

8. Martin RC, Hughes K, Doll MA, Lan Q, Martini BD, Lissowska J, Rothman N, Hein DW. Method for determination of (-102C>T) single nucleotide polymorphism in the human manganeso superoxide dismutase promoter. BMC Genet. 2004;14;5(1):33

9. Li H, Kantoff PW, Giovannucci E, Leitzmann MF, Gaziano JM, Stampfer MJ, Ma J. Manganese Superoxide Dismutase Polymorphism, Prediagnostic Antioxidant Status, and Risk of Clinical Significant Prostate Cancer. Cancer Res. 2005;65(6):2498-504.

10. Gonzalo ML, Isaacs WB. Molecular pathways to prostate cancer. J Urol. 2003; 170(6 Pt 1):2444-52

11. Mc Cord JM, Fridovich I. Superoxide Dismutase: an enzyme function for erythrocuprein (hemocuprein). J Biol Chem. 1969;25;244(22):6049-55.

12. Bostwick DG, Alexander EE, Singh R, Shan A, Qian J, Santella RM, et al. Antioxidant enzyme expression and reactive oxygen species damage in prostatic intraepithelial neoplasia and cancer. Cancer. 2000;89(1):123-34.

13. Hu Y, Rosen DG, Zhou Y, Feng L, Yang G, Liu J, Huang P. Mytochondrial Manganeso-Superoxide Dismutase expression in ovarian cáncer. J Biol Chem. 2005;25; 280(47):39485-92.